Columvi

Active Ingredient(s): Glofitamab-gxbm
FDA Approved: * June 15, 2023
Pharm Company: * GENENTECH INC
Category: Cancer
* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Columvi 2.5 mg/2.5ml Intravenous Solution, Concentrate
NDC: 50242-125
Labeler:
Genentech, Inc.
Columvi 10 mg/10ml Intravenous Concentrate
NDC: 50242-127
Labeler:
Genentech, Inc.